cabazitaxel (jevtana kit) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cabazitaxel (JEVTANA®) is an antineoplastic agent belonging to the taxane class and is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. It is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). Cabazitaxel (JEVTANA®) is a microtubule inhibitor. It binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.   NCATS

Chemistry

  • SMILES: CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)C4=CC=CC=C4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6)C(C)=C([C@@H](OC)C(=O)[C@]13C)C5(C)C
  • InChIKey: BMQGVNUXMIRLCK-OAGWZNDDSA-N
  • Mol. Mass: 835.9324
  • ALogP: 4.57
  • ChEMBL Molecule:
    cabazitaxel  
More Chemistry

Pharmacology

Alternative names

4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate | cabacitaxel | cabazitaxel | cabazitaxel acetonate | cabazitaxel acetone | cabazitaxel, docetaxel, mitoxantrone or satraplatin | cabazitaxelum | javtana | jevtana | jevtana kit | rpr-116258a | taxoid xrp6258 | txd258 | txd 258 | txd-258 | xrp6258 | xrp-6258

Organizations (159)

Research & Development (148)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (44)

Approved Indications (1)


 

Prostatic Neoplasms (approved 2010)

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Adrenocortical Carcinoma (Phase 2)

Anemia (Phase 1)

Brain Neoplasms (Phase 1/Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2/Phase 3)

Castration (Phase 2)

Colorectal Neoplasms (Phase 2)

Diarrhea (Phase 2)

Drug Therapy (Phase 2)

Esophageal Diseases (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Hodgkin Disease (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1)

Leukemia, Myeloid, Chronic-Phase (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Liposarcoma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphadenopathy (Phase 1/Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasm Metastasis (Phase 2/Phase 3)

Neoplasms ()

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neoplastic Cells, Circulating (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Penile Neoplasms (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 1)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Testicular Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 107
  • # of Trial Organizations: 148

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue